Mr. Collard joined Veloxis in December of 2015 as the Chief Executive Officer. He has over 23 years of experience in the pharmaceutical industry.
Mr. Collard is currently a Board member of BioMarck Pharmaceuticals and Hilltop Home Foundation. In 2003, Mr. Collard found Cornerstone Therapeutics where he became Chairman and CEO and was later sold to Chiesi Farmaceutici (2014).
Mr. Collard started his career at Dura Pharmaceuticals where he served in numerous sales and marketing roles within the Company. He left Dura in 1998 and joined DJ Pharma, Inc, which was sold to Biovail in 2000.
Mr. Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University) in Marietta, Georgia.
Mr. Stilou joined Veloxis in April 2008. He is responsible for the activities within Finance, IT, Legal Affairs, and Investor Relations.
Dr. John Weinberg, MD
Dr. Weinberg joined Veloxis in July 2010. He is responsible for managing all commercial activities supporting the Veloxis portfolio of compounds in development. Additionally, Dr. Weinberg directs Corporate Strategy and Pipeline Target Identification.
Ms. Sylvest joined Veloxis in April 2008. She is responsible for clinical development, clinical operations, and drug supply.
Mr. Breian Knudsen
Mr. Knudsen joined Veloxis in November 2007. He is responsible for technology transfer, process validation, and clinical and commercial manufacturing.
Mr. Knudsen has extensive experience within process and product development, technology transfer, process validation, and manufacture within the pharmaceutical industry.
Prior to joining Veloxis, Mr. Knudsen held a position as Principal Scientist, Chemistry Manufacturing & Controls (CMC) project manager at Novo Nordisk A/S, where he headed the CMC part of a number of solid dosage development projects and where he implemented guidelines for systematic in-house and external transfer of manufacturing processes.
Mr. Knudsen holds an MSc degree in Pharmacy from the Pharmaceutical University of Copenhagen.
Ron Guido has been employed in pharmaceutical development since 1980, in the areas of preclinical screening, clinical research, regulatory affairs, product development, and quality systems. Experience includes development strategy, merger and acquisition, as well as commercial support for new and marketed products. Past positions include Vice-President Regulatory, Retrophin, Inc; Senior Director and Therapeutic Area Head for Cardiovascular Medicine – Worldwide Regulatory Strategy for Pfizer, as well as senior roles with V.I. Technologies/ Precision Pharma Services, Whitehall-Robins Healthcare, Fresenius Pharma USA, and Wyeth-Ayerst Laboratories.
Mar 9, 2016
Release of Annual Report 2015
Mar 9, 2016
Offentliggørelse af årsrapport for 2015
Apr 6, 2016
Apr 6, 2016
Annual General Meeting